24 May 2016 - This guidance replaces NICE technology appraisal guidance on the use of cabazitaxel in patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Cabazitaxel in combination with prednisone or prednisolone is recommended as an option for treating metastatic hormone‑relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy, only if:

• the person has an eastern cooperative oncology group (ECOG) performance status of 0 or 1
• the person has had 225 mg/m2 or more of docetaxel
• treatment with cabazitaxel is stopped when the disease progresses or after a maximum of 10 cycles (whichever happens first)
• NHS trusts purchase cabazitaxel in pre‑prepared intravenous‑infusion bags, not in vials, and
• the company provides cabazitaxel with the discount agreed in the patient access scheme.

For more details, go to: https://www.nice.org.uk/guidance/ta391/chapter/1-Recommendations